Table 2.
Surgical characteristics and fungal prophylaxis.
| Overall (n = 157, 100%) |
FI (n = 13, 8%) |
Fungal Colonization (n = 36, 23%) |
Others (n = 108, 69%) |
p-Value | |
|---|---|---|---|---|---|
| Surgical characteristics | |||||
| Time from LT, days, median (IQR) | 420 (365–480) | 430 (382–450) | 435 (378–502) | 420 (359–481) | 0.64 |
| Time of graft ischemia, days, median (IQR) | 560 (441–655) | 563 (461–731) | 575 (433–696) | 553 (452–630) | 0.51 |
| Intraoperative ECMO, n (%) | 103 (66) | 8 (62) | 26 (72) | 77 (71) | 0.75 |
| Surgical revision, n (%) | 29 (18) | 4 (31) | 10 (28) | 15 (14) | 0.09 |
| Prolonged ECMO, n (%) | 29 (18) | 5 (38) | 8 (22) | 16 (15) | 0.22 |
| Duration of prolonged ECMO, days, median (IQR) | 2 (0–3) | 3 (1–8.75) | 3 (2–4) | 1 (0–3) | 0.79 |
| During ICU stay | |||||
| Immunosuppressive therapy +, n (%) | 93 (59) | 9 (69) | 24 (67) | 60 (56) | 0.50 |
| Renal replacement therapy, n (%) | 24 (17) | 3 (23) | 8 (22) | 13 (12) | 0.30 |
| Antifungal therapies * and biomarkers | |||||
| Universal prophylaxis, n (%) | |||||
| (i) Liposomal amphotericin B i.v. plus inhaled amphotericin B lipid complex | 112 (71) | 9 (69) | 25 (69) | 78 (72) | 0.79 |
| (ii) Liposomal amphotericin B i.v. | 33 (21) | 2 (15) | 6 (17) | 25 (23) | 0.79 |
| (iii) Azoles or echinocandins | 12 (8) | 2 (15) | 5 (14) | 5 (5) | 0.79 |
| Mycological culture, n (%) | 49 (31) | 13 (100) | 36 (100) | - | 0.99 |
| BAL galactomannan antigen, ratio | 0 [0–3] | 4 [1–6] | 0 [0–2] | - | <0.001 |
| BAL galactomannan antigen > b1, n (%) | 12 (8) | 6 (46) | 6 (17) | - | 0.17 |
| β-D-glucan (reference > 80 pg/mL), n (%) | 8 (5) | 3 (23) | 5 (14) | - | 0.72 |
Data are expressed as number and (percentage) or median and [interquartile range]. *: additional information is available in Table 3. Abbreviations: FI, Fungal Infection; LT, lung transplant; n, number; ECMO, extracorporeal membrane oxygenation; i.v., intravenous; min, minutes; BAL, bronco-alveolar lavage; OR, odds ratio; IQR, interquartile range. + Immunosuppressive therapy was cyclosporine as reference.